Transfusion Related Acute Lung Injury

Image 3. Pathogenesis of TRALI. Transfused HLA and HNA antibodies prime and
activate a recipient’s neutrophils by binding to them directly causing transfusion related
acute lung injury.
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Clinical Case
A 74 year old woman presented with hematemesis. Her medical
history was significant for pulmonary embolism treated with warfarin
anticoagulation, fibromyalgia treated with NSAIDs/steroids, and a prior
bleeding event from a gastric ulcer. On admission she was stable with
a hemoglobin of 8.7 g/dL and a therapeutic INR of 3.19. A type and
screen determined a blood type of AB positive. In anticipation of
endoscopy, the patient received one unit of red blood cells and four
units of type AB plasma. Following transfusion, her INR was 1.83. The
patient received an additional four units of type AB plasma to further
correct her INR. Endoscopy identified a medium-sized gastric ulcer.
Shortly after completion of the endoscopy, the patient became hypoxic
and began experiencing dyspnea and frothy oral secretions. A chest xray 1 hour after the start of the reaction showed diffuse pulmonary
edema without cardiomegaly (image 1). The patient was intubated
within 2 hours of the reaction and a chest x-ray showed increasingly
diffuse pulmonary edema with small bilateral pulmonary effusions
(image 2). Ventilator and pressor support were required for several
days, and the patient was extubated five days after the reaction. The
clinical team and transfusion service strongly suspected Transfusion
Related Acute Lung Injury (TRALI) and contacted the blood supplier.
The blood supplier determined the Human Leukocyte Antigen (HLA)
Class I/II type of the patient and pursued HLA antibody screening for
the donors of the four plasma units transfused most proximal to the
reaction. Three of the four donors were parous females and returned
for HLA antibody screening, while the fourth male donor could not be
contacted. Of the three tested donors, none had Human Neutrophil
Antigen (HNA) antibodies. Two of the three tested donors had HLA
Class I/II antibodies that were non-cognate with the patient. One of the
three tested donors had extensive HLA Class I/ II antibodies which
were cognate with 4 of 6 of the patient’s HLA Class I antigens and 4 of
6 of the patient’s Class II antigens. The implicated donor was deferred
from further donation.

Image 1. X-ray at 1 hour post reaction
showing diffuse pulmonary edema without
cardiomegaly

Image 2. X-ray at 2 hour post reaction showing
increasingly diffuse pulmonary edema and
small bilateral pulmonary effusions

INTRODUCTION
TRALI (defined in Table 1), is an
under-recognized immunemediated transfusion
complication that causes noncardiogenic pulmonary edema.
From 2007 to 2011, TRALI was
the leading cause of transfusionrelated fatalities reported to the
Federal Drug Administration and
accounted for 43% of
transfusion related fatalities.

Table 1. Definition of TRALI
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PATHOGENESIS
TRALI is an immune mediated event. The proposed mechanism for
TRALI involves donor antibodies present in the transfused blood
component reacting with cognate antigens on a recipient’s
neutrophils (PMNs). The donor antibodies can be anti-HLA Class I/
II or anti-HNA. Via unknown mechanisms, antibody coated PMNs
localize to the pulmonary microvasculature and become primed for
complement activation. Complement activation causes PMNs to
release proteases, oxygen radicals, and acidic lipids, thereby
damaging the pulmonary vascular endothelium. This allows for the
leakage of fluids into the adjacent pulmonary interstitium and alveoli,
resulting in pulmonary edema and the symptoms of TRALI (image 3).
Alloimmunizing events that may cause donors to form anti-HLA or
anti-HNA antibodies include pregnancy and previous blood
transfusion. Strategies implemented to prevent TRALI have
decreased the number of cases overall, but the risk of TRALI
remains. In the case of plasma transfusion, limiting supplies to male
donors only (low risk of alloimmunization) has reduced TRALI.

CLINICAL PRESENTATION
The symptoms of TRALI include hypoxemia, tachycardia, fever, mild
hypotension, cyanosis, and bilateral non-cardiogenic pulmonary
edema that progresses to involve the entire lung fields. Patients have
a normal central venous pressure and low to normal pulmonary
wedge pressure. These symptoms have a rapid onset and
progression and always present within 6 hours of transfusion of
plasma-containing blood components. The diagnosis of TRALI is
made clinically and is confirmed by HLA typing the recipient and
testing donor serum for the presence of HLA or HNA antibodies. A
cognate match between a donor antibody and recipient antigen
confirms the diagnosis of TRALI.

MANAGEMENT
Treatment of TRALI is supportive.
1) Respiratory support in the form of oxygen supplementation and/or
intubation, as needed.
2) Hypotension should be treated with IV fluids and vasopressors if
refractory.
A chest x-ray should be ordered and capillary wedge pressures
measured. Suspected TRALI cases must be reported to the blood
bank and a sample of the patient’s blood taken for further
investigation. As a donor antibody is the causative factor in TRALI,
no special accommodations are necessary for the patient to receive
future transfusions. With aggressive and prompt support,
approximately 80% of TRALI patients improve within 48 to 96 hours
after the original insult.

PREVENTION
TRALI prevention strategies primarily focus on limiting the use of
plasma products of donors who are most likely to have HLA
antibodies. Strategies include, but are not limited to:
1) Permanent deferral of donors implicated in TRALI reactions.
2) Near-exclusive use of plasma from male donors. Due to the
rarity of blood type AB and the high demand for universal donor
AB plasma, this exclusivity does not apply to type AB plasma
products. This is demonstrated in the above case.
3) Minimize the inappropriate transfusion of blood components
4) Develop plasma-reduced components

CONCLUSION
The patient’s clinical course was consistent with TRALI, with cognate
patient HLA antigens and donor HLA antibodies confirming the
diagnosis. Implementation of new prevention strategies is needed to
address this elevated risk and further reduce TRALI cases in the
future.
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